Physician profile
Mark B Real
NPI 1295871598
$3,511.63
in general payments reported to CMS, 2019-2025
40 companies · $14.77 in 2025
The $14.77 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,200 · 2020: $386 · 2021: $707 · 2023: $100 · 2024: $103 · 2025: $14.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $489.36 | 2019-2021 | |
| Novo Nordisk INC | $439.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $377.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $274.11 | 2019-2021 | |
| Pfizer INC. | $226.10 | 2019-2021 | |
| Lilly USA, LLC | $215.89 | 2019-2021 | |
| Glaxosmithkline, LLC. | $162.86 | 2019-2024 | Arexvy |
| Abbvie INC. | $144.03 | 2019-2021 | |
| Cook Medical LLC | $100.00 | 2023 | Hemospray |
| Novartis Pharmaceuticals Corporation | $94.51 | 2019-2021 | |
| Ucb, INC. | $88.31 | 2019-2021 | |
| Astellas Pharma US INC | $78.25 | 2019-2020 | |
| Amarin Pharma, INC. | $74.32 | 2019-2021 | |
| Becton, Dickinson and Company | $72.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $64.91 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Real listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.